AI Engines For more Details: Perplexity Kagi Labs You
Antispasmodic Effects: Methantheline bromide works by blocking muscarinic receptors, which are receptors for the neurotransmitter acetylcholine. By inhibiting these receptors, it reduces smooth muscle contractions in the GI tract and urinary bladder. This effect can help alleviate symptoms of conditions such as irritable bowel syndrome (IBS), overactive bladder, and bladder spasms.
GI Disorders: Methantheline bromide is commonly used to treat symptoms of GI disorders characterized by spasms, including abdominal cramps, bloating, and diarrhea. It may be prescribed for conditions such as IBS, functional dyspepsia, and diverticulitis.
Urinary Disorders: In addition to its GI effects, methantheline bromide can help reduce bladder spasms and urinary urgency associated with conditions like overactive bladder and neurogenic bladder.
Side Effects: Common side effects of methantheline bromide include dry mouth, blurred vision, constipation, urinary retention, and decreased sweating. These side effects are due to its anticholinergic properties, which can affect various systems in the body.
Cautions and Contraindications: Methantheline bromide should be used with caution in individuals with certain medical conditions, such as narrow-angle glaucoma, urinary retention, prostatic hypertrophy, and myasthenia gravis. It may also interact with other medications, so it's important for healthcare providers to review a patient's complete medical history and current medication regimen before prescribing methantheline bromide.
Dosage and Administration: Methantheline bromide is typically taken orally in tablet or liquid form. The dosage and frequency of administration depend on the individual's condition and response to treatment. It is important to follow the healthcare provider's instructions and not exceed the prescribed dose.
Monitoring: Patients taking methantheline bromide may require periodic monitoring to assess their response to treatment and monitor for any potential side effects or complications.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| ADHD | 0.7 | 0.5 | 0.4 |
| Age-Related Macular Degeneration and Glaucoma | 0.3 | 0.3 | |
| Allergic Rhinitis (Hay Fever) | 1.1 | 1.1 | |
| Allergies | 0.7 | 0.5 | 0.4 |
| Allergy to milk products | 0.4 | 0.1 | 3 |
| Alzheimer's disease | 1.1 | 3.4 | -2.09 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.1 | 0.3 | 2.67 |
| Ankylosing spondylitis | 0.9 | 1 | -0.11 |
| Anorexia Nervosa | 0.8 | -0.8 | |
| Antiphospholipid syndrome (APS) | 1 | 0.3 | 2.33 |
| Asthma | 0.4 | -0.4 | |
| Atherosclerosis | 0 | 0.9 | 0 |
| Atrial fibrillation | 1.1 | 1.1 | 0 |
| Autism | 3.5 | 3.8 | -0.09 |
| Barrett esophagus cancer | 0 | 0 | 0 |
| benign prostatic hyperplasia | 0.1 | 0.1 | |
| Bipolar Disorder | 0.6 | 0.8 | -0.33 |
| Brain Trauma | 0.4 | -0.4 | |
| Carcinoma | 0.6 | 0.1 | 5 |
| Celiac Disease | 1.2 | 0.5 | 1.4 |
| Cerebral Palsy | 0 | 0.4 | 0 |
| Chronic Fatigue Syndrome | 1.2 | 2.4 | -1 |
| Chronic Kidney Disease | 1.3 | 1.6 | -0.23 |
| Chronic Lyme | 0.4 | -0.4 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | 0.8 | -7 |
| Chronic Urticaria (Hives) | 0.5 | 0.9 | -0.8 |
| Coagulation / Micro clot triggering bacteria | 0.5 | 0.3 | 0.67 |
| Colorectal Cancer | 1.5 | 0.4 | 2.75 |
| Constipation | 1 | 0.3 | 2.33 |
| Coronary artery disease | 1.2 | 0.5 | 1.4 |
| COVID-19 | 0.8 | 4.1 | -4.12 |
| Crohn's Disease | 3 | 2.2 | 0.36 |
| cystic fibrosis | 0.4 | 0.4 | 0 |
| deep vein thrombosis | 0.4 | 0.3 | 0.33 |
| Depression | 1.6 | 3.3 | -1.06 |
| Dermatomyositis | 0 | 0 | |
| Eczema | 0.9 | 0.5 | 0.8 |
| Endometriosis | 1.1 | 1.1 | |
| Eosinophilic Esophagitis | 0 | 0 | |
| Epilepsy | 0.8 | 0.1 | 7 |
| Fibromyalgia | 0.3 | 1.6 | -4.33 |
| Functional constipation / chronic idiopathic constipation | 2.3 | 2.1 | 0.1 |
| gallstone disease (gsd) | 0.1 | 0.3 | -2 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.2 | 0 | 0 |
| Generalized anxiety disorder | 1.3 | 0.6 | 1.17 |
| Glioblastoma | 0 | 0 | |
| Gout | 0.5 | -0.5 | |
| Graves' disease | 0.1 | 0.3 | -2 |
| Halitosis | 0.2 | 0 | 0 |
| Hashimoto's thyroiditis | 0.7 | 0.5 | 0.4 |
| Hidradenitis Suppurativa | 0.4 | 0.4 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.5 | 0.7 | 1.14 |
| hyperglycemia | 0.1 | 0.1 | 0 |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.3 | 1.7 | -4.67 |
| Hypothyroidism | 0.5 | -0.5 | |
| Hypoxia | 0.1 | 0.1 | |
| IgA nephropathy (IgAN) | 1.4 | -1.4 | |
| Inflammatory Bowel Disease | 1.9 | 3.6 | -0.89 |
| Insomnia | 0.2 | 0.4 | -1 |
| Intelligence | 0.5 | 0.5 | 0 |
| Intracranial aneurysms | 0.1 | 0.1 | |
| Irritable Bowel Syndrome | 1 | 1.2 | -0.2 |
| Liver Cirrhosis | 1.5 | 1.3 | 0.15 |
| Long COVID | 3.5 | 1.8 | 0.94 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.1 | 0.1 | |
| ME/CFS with IBS | 0.2 | 1.1 | -4.5 |
| ME/CFS without IBS | 0.9 | 0.1 | 8 |
| Metabolic Syndrome | 3 | 2.5 | 0.2 |
| Mood Disorders | 2.4 | 3.3 | -0.38 |
| multiple chemical sensitivity [MCS] | 0.1 | 0.1 | |
| Multiple Sclerosis | 0.4 | 2.1 | -4.25 |
| Neuropathy (all types) | 0 | 0.1 | 0 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.6 | 1.4 | -1.33 |
| Obesity | 2.5 | 0.8 | 2.13 |
| obsessive-compulsive disorder | 1.8 | 2.5 | -0.39 |
| Osteoarthritis | 1.1 | 1.1 | |
| Osteoporosis | 0.3 | 0.1 | 2 |
| pancreatic cancer | 0 | 0 | |
| Parkinson's Disease | 1.1 | 2.4 | -1.18 |
| Polycystic ovary syndrome | 1 | 0.3 | 2.33 |
| Postural orthostatic tachycardia syndrome | 0.5 | -0.5 | |
| Psoriasis | 0.8 | 1.4 | -0.75 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.7 | 1.4 | 0.93 |
| Rosacea | 0.3 | 0.3 | 0 |
| Schizophrenia | 1 | 0.8 | 0.25 |
| scoliosis | 0.5 | 0.3 | 0.67 |
| Sjögren syndrome | 0.6 | 0.5 | 0.2 |
| Sleep Apnea | 0.5 | 0.9 | -0.8 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.4 | 0.4 | |
| Stress / posttraumatic stress disorder | 0.8 | 0.9 | -0.13 |
| Systemic Lupus Erythematosus | 2.4 | 0.3 | 7 |
| Tic Disorder | 0.7 | 0.5 | 0.4 |
| Tourette syndrome | 0.1 | -0.1 | |
| Type 1 Diabetes | 2.3 | 1.1 | 1.09 |
| Type 2 Diabetes | 3.7 | 2.6 | 0.42 |
| Ulcerative colitis | 0.6 | 2.4 | -3 |
| Unhealthy Ageing | 3.4 | 1.6 | 1.13 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.